Top

18-12-2024 | Type 2 Diabetes | Article

Dose-related effects of intraduodenal quinine on plasma glucose, glucoregulatory hormones and gastric emptying of a nutrient drink, and energy intake, in men with type 2 diabetes: a double-blind, randomised, crossover study

Authors: Vida Bitarafan, Javad Anjom-Shoae, Peyman Rezaie, Penelope C. E. Fitzgerald, Kylie Lange, Michael Horowitz, Christine Feinle-Bisset

Published in: Diabetologia

Abstract

Aims/hypothesis

Quinine, when administered intraduodenally to activate bitter-taste receptors, in a dose of 600 mg, stimulates glucagon-like peptide-1 (GLP-1) and insulin, slows gastric emptying and lowers postprandial glucose in healthy people, with consequent implications for the management of type 2 diabetes; the effect of quinine on energy intake is uncertain. We have investigated the dose-related effects of quinine on postprandial blood glucose levels and energy intake in people with type 2 diabetes.

Methods

Male participants with type 2 diabetes (age: 68±5 years; HbA_1c: 49.0±5.0 mmol/mol [6.7±0.4%], BMI: 30±1 kg/m²) received in two study parts (A and B, n=12 each), on three separate occasions each, in randomised, crossover fashion, control, or 300 mg (QHCl-300) or 600 mg (QHCl-600) quinine hydrochloride, intraduodenally 30 min before a nutrient drink (2092 kJ, 74 g carbohydrate) (part A) or a standardised buffet-lunch (part B). Both the participants and investigators performing the study procedures were blinded to the treatments. In part A, plasma glucose, GLP-1, C-peptide and glucagon were measured at baseline, for 30 min after quinine alone and for 3 h post drink. Gastric emptying of the drink was measured with a ¹³C-acetate breath test. In part B, energy intake from the buffet-lunch was quantified.

Results

Quinine alone had no effect. Post drink, both quinine doses reduced peak plasma glucose markedly (QHCl-600 by 2.8±0.6 mmol/l) and slowed gastric emptying (all p<0.05; n=12, except for gastric emptying, n=11). QHCl-600, but not QHCl-300, stimulated plasma GLP-1 and C-peptide modestly (both p<0.05). Quinine did not affect energy intake.

Conclusions/interpretation

In type 2 diabetes, acute intraduodenal administration of quinine markedly reduces the plasma glucose response to oral carbohydrate, but does not affect energy intake. These findings support the potential use of quinine to reduce postprandial blood glucose levels in type 2 diabetes.

Trial registration

anzctr.org.au ACTRN12620000972921/ACTRN12621000218897

Funding

The study was funded by a Diabetes Australia Research Project Grant.

Graphical Abstract

Available only for authorised users

Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J (2011) Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 34(12):2508–2514. https://doi.org/10.2337/dc11-0632CrossRefPubMedPubMedCentral

Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M (2015) Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol 11(2):112–128. https://doi.org/10.1038/nrendo.2014.202CrossRefPubMed

Feltrin KL, Little TJ, Meyer JH et al (2004) Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am J Physiol Regul Integr Comp Physiol 287(3):R524-533. https://doi.org/10.1152/ajpregu.00039.2004CrossRefPubMed

Ma J, Stevens JE, Cukier K et al (2009) Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32(9):1600–1602. https://doi.org/10.2337/dc09-0723CrossRefPubMedPubMedCentral

Ryan AT, Luscombe-Marsh ND, Saies AA et al (2013) Effects of intraduodenal lipid and protein on gut motility and hormone release, glycemia, appetite, and energy intake in lean men. Am J Clin Nutr 98(2):300–311. https://doi.org/10.3945/ajcn.113.061333CrossRefPubMed

van Avesaat M, Troost FJ, Ripken D, Peters J, Hendriks HF, Masclee AA (2015) Intraduodenal infusion of a combination of tastants decreases food intake in humans. Am J Clin Nutr 102(4):729–735. https://doi.org/10.3945/ajcn.115.113266CrossRefPubMed

Rezaie P, Bitarafan V, Horowitz M, Feinle-Bisset C (2021) Effects of bitter substances on GI function, energy intake and glycaemia-do preclinical findings translate to outcomes in humans? Nutrients 13(4):1317. https://doi.org/10.3390/nu13041317CrossRefPubMedPubMedCentral

Okitolonda W, Delacollette C, Malengreau M, Henquin JC (1987) High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria. Br Med J (Clin Res Ed) 295(6600):716–718. https://doi.org/10.1136/bmj.295.6600.716CrossRefPubMed

Henquin JC (1982) Quinine and the stimulus-secretion coupling in pancreatic β-cells: glucose-like effects on potassium permeability and insulin release. Endocrinology 110(4):1325–1332. https://doi.org/10.1210/endo-110-4-1325CrossRefPubMed

10.

Taylor TE, Molyneux ME, Wirima JJ, Fletcher KA, Morris K (1988) Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N Engl J Med 319(16):1040–1047. https://doi.org/10.1056/nejm198810203191602CrossRefPubMed

11.

Njomatchoua AC, Tankeu AT, Sobngwi E, Mbanya J-C (2017) Glycemic effects of quinine infusion in healthy volunteers. BMC Research Notes 10(1):423. https://doi.org/10.1186/s13104-017-2744-0CrossRefPubMedPubMedCentral

12.

Imai H, Hakukawa M, Hayashi M, Iwatsuki K, Masuda K (2020) Expression of bitter taste receptors in the intestinal cells of non-human primates. Int J Mol Sci 21(3):902. https://doi.org/10.3390/ijms21030902CrossRefPubMedPubMedCentral

13.

Wu SV, Rozengurt N, Yang M, Young SH, Sinnett-Smith J, Rozengurt E (2002) Expression of bitter taste receptors of the T2R family in the gastrointestinal tract and enteroendocrine STC-1 cells. Proc Natl Acad Sci U S A 99(4):2392–2397. https://doi.org/10.1073/pnas.042617699CrossRefPubMedPubMedCentral

14.

Bitarafan V, Fitzgerald PCE, Little TJ et al (2020) Intragastric administration of the bitter tastant quinine lowers the glycemic response to a nutrient drink without slowing gastric emptying in healthy men. Am J Physiol Regul Integr Comp Physiol 318(2):R263–R273. https://doi.org/10.1152/ajpregu.00294.2019CrossRefPubMed

15.

Rose BD, Bitarafan V, Rezaie P, Fitzgerald PCE, Horowitz M, Feinle-Bisset C (2021) Comparative effects of intragastric and intraduodenal administration of quinine on the plasma glucose response to a mixed-nutrient drink in healthy men: relations with glucoregulatory hormones and gastric emptying. J Nutr 151(6):1453–1461. https://doi.org/10.1093/jn/nxab020CrossRefPubMed

16.

Rezaie P, Bitarafan V, Rose BD et al (2022) Quinine effects on gut and pancreatic hormones and antropyloroduodenal pressures in humans-role of delivery site and sex. J Clin Endocrinol Metab 107(7):E2870–E2881. https://doi.org/10.1210/clinem/dgac182CrossRefPubMedPubMedCentral

17.

Rezaie P, Bitarafan V, Rose BD et al (2023) Effects of quinine on the glycaemic response to, and gastric emptying of, a mixed-nutrient drink in females and males. Nutrients 15(16):3584. https://doi.org/10.3390/nu15163584CrossRefPubMedPubMedCentral

18.

Andreozzi P, Sarnelli G, Pesce M et al (2015) The bitter taste receptor agonist quinine reduces calorie intake and increases the postprandial release of cholecystokinin in healthy subjects. J Neurogastroenterol Motil 21(4):511–519. https://doi.org/10.5056/jnm15028CrossRefPubMedPubMedCentral

19.

Iven J, Biesiekierski JR, Zhao D et al (2019) Intragastric quinine administration decreases hedonic eating in healthy women through peptide-mediated gut-brain signaling mechanisms. Nutr Neurosci 22(12):850–862. https://doi.org/10.1080/1028415X.2018.1457841CrossRefPubMed

20.

Bitarafan V, Fitzgerald PCE, Little TJ et al (2019) Effects of intraduodenal infusion of the bitter tastant, quinine, on antropyloroduodenal motility, plasma cholecystokinin, and energy intake in healthy men. J Neurogastroenterol Motil 25(3):413–422. https://doi.org/10.5056/jnm19036CrossRefPubMedPubMedCentral

21.

Kautzky-Willer A, Harreiter J, Pacini G (2016) Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 37(3):278–316. https://doi.org/10.1210/er.2015-1137CrossRefPubMedPubMedCentral

22.

Ewing DJ, Clarke BF (1982) Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 285(6346):916–918. https://doi.org/10.1136/bmj.285.6346.916CrossRefPubMed

23.

Chale-Rush A, Burgess JR, Mattes RD (2007) Evidence for human orosensory (taste?) sensitivity to free fatty acids. Chem Senses 32(5):423–431. https://doi.org/10.1093/chemse/bjm007CrossRefPubMed

24.

Heddle R, Dent J, Toouli J, Read NW (1988) Topography and measurement of pyloric pressure waves and tone in humans. Am J Physiol 255(4 Pt 1):G490–G497. https://doi.org/10.1152/ajpgi.1988.255.4.G490CrossRefPubMed

25.

Nair NS, Brennan IM, Little TJ et al (2009) Reproducibility of energy intake, gastric emptying, blood glucose, plasma insulin and cholecystokinin responses in healthy young males. Br J Nutr 101(7):1094–1102. https://doi.org/10.1017/s0007114508042372CrossRefPubMed

26.

Mossi S, Meyer-Wyss B, Beglinger C et al (1994) Gastric emptying of liquid meals measured noninvasively in humans with [13C]acetate breath test. Dig Dis Sci 39(12 Suppl):107S-109S. https://doi.org/10.1007/BF02300386CrossRefPubMed

27.

Parker BA, Sturm K, MacIntosh CG, Feinle C, Horowitz M, Chapman IM (2004) Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur J Clin Nutr 58(2):212–218. https://doi.org/10.1038/sj.ejcn.1601768CrossRefPubMed

28.

Saisho Y (2016) Postprandial C-peptide to glucose ratio as a marker of β cell function: implication for the management of type 2 diabetes. Int J Mol Sci 17(5):744. https://doi.org/10.3390/ijms17050744CrossRefPubMedPubMedCentral

29.

Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D’Alessio DA (2006) β-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab 91(1):185–191. https://doi.org/10.1210/jc.2005-0853CrossRefPubMed

30.

Elder DA, Woo JG, D’Alessio DA (2010) Impaired β-cell sensitivity to glucose and maximal insulin secretory capacity in adolescents with type 2 diabetes. Pediatr Diabetes 11(5):314–321. https://doi.org/10.1111/j.1399-5448.2009.00601.xCrossRefPubMedPubMedCentral

31.

Avau B, Rotondo A, Thijs T et al (2015) Targeting extra-oral bitter taste receptors modulates gastrointestinal motility with effects on satiation. Sci Rep 5(1):15985. https://doi.org/10.1038/srep15985CrossRefPubMedPubMedCentral

32.

Deane AM, Nguyen NQ, Stevens JE et al (2010) Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95(1):215–221. https://doi.org/10.1210/jc.2009-1503CrossRefPubMed

33.

Schirra J, Nicolaus M, Roggel R et al (2006) Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55(2):243–251. https://doi.org/10.1136/gut.2004.059741CrossRefPubMedPubMedCentral

34.

Baggio LL, Drucker DJ (2021) Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab 46:101090. https://doi.org/10.1016/j.molmet.2020.101090CrossRefPubMed

35.

Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK (2017) Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences. Diabetes Obes Metab 19(5):672–681. https://doi.org/10.1111/dom.12872CrossRefPubMedPubMedCentral

36.

Klaassen T, Keszthelyi D, Troost FJ, Bast A, Masclee AAM (2021) Effects of gastrointestinal delivery of non-caloric tastants on energy intake: a systematic review and meta-analysis. Eur J Nutr 60(6):2923–2947. https://doi.org/10.1007/s00394-021-02485-4CrossRefPubMedPubMedCentral

37.

Klaassen T, Keszthelyi D, Alleleyn AME et al (2021) Effect of oral or intragastric delivery of the bitter tastant quinine on food intake and appetite sensations: a randomised crossover trial. Br J Nutr 125(1):92–100. https://doi.org/10.1017/S0007114520002536CrossRefPubMed

38.

Goyal RK, Guo Y, Mashimo H (2019) Advances in the physiology of gastric emptying. Neurogastroenterol Motil 31(4):e13546. https://doi.org/10.1111/nmo.13546CrossRefPubMedPubMedCentral

39.

Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N (2017) Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97(1):411–463. https://doi.org/10.1152/physrev.00031.2014CrossRefPubMed

Title: Dose-related effects of intraduodenal quinine on plasma glucose, glucoregulatory hormones and gastric emptying of a nutrient drink, and energy intake, in men with type 2 diabetes: a double-blind, randomised, crossover study
Authors: Vida Bitarafan
Javad Anjom-Shoae
Peyman Rezaie
Penelope C. E. Fitzgerald
Kylie Lange
Michael Horowitz
Christine Feinle-Bisset
Publication date: 18-12-2024
Publisher: Springer Berlin Heidelberg
Keyword: Type 2 Diabetes
Published in: Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-024-06344-9

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now